Sorafenib and Dacarbazine in Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
SarcomaSynovial SarcomaLeiomyosarcomaMalignant Peripheral Nerve Sheath Tumor
Interventions
DRUG

Sorafenib and Dacarbazine

"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00837148 - Sorafenib and Dacarbazine in Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter